Press Releases

GlobeNewswire, Inc.

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in...

GlobeNewswire, Inc.

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data Immunomodulator-free...

GlobeNewswire, Inc.

- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 - - Additional one-year clinical data from Phase 1/2 ACHIEVE trial of...

GlobeNewswire, Inc.

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD), the omnichannel outcomes platform (the “Company” or “Teads”), today announced the appointment of Michael Coyle as Chief Financial Officer, effective November 11, 2026....

GlobeNewswire, Inc.

RENO, Nev., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in lithium battery technology, today announced that the Company will release its financial and...

GlobeNewswire, Inc.

Revenue was $809 million, up 5.3%, and up 7.4% on an organic constant currency (OCC) basis, a non-GAAP measure.

GlobeNewswire, Inc.

Third Quarter Revenue of $42.7 Million, Up 12% Year-over-Year Exchange Revenue Grew 24% Year-over-Year to $25.5 Million Adjusted EBITDA of $1.1 Million vs $0.2 Million in the Prior Year (All monetary figures are expressed in Canadian dollars...

GlobeNewswire, Inc.

Third quarter milestones included a definitive power agreement that removes approximately $33 million of upfront costs from the construction budget and enactment of new Brazilian legislation, Profert, favorable to the Company Front End Engineering...

GlobeNewswire, Inc.

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by...

GlobeNewswire, Inc.

- PDUFA target action date of May 27, 2027, following FDA acceptance of obexelimab BLA submission for the treatment of IgG4-RD in August 2026 - - Obexelimab MAA submitted to the EMA for the treatment of IgG4-RD - - New data presented at IgG4ward!...

GlobeNewswire, Inc.

Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC) showed compelling efficacy data with a manageable safety profile FDA feedback on dose selection from the...

GlobeNewswire, Inc.

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third...

GlobeNewswire, Inc.

Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year Purified Cortrophin® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year Quarterly GAAP net income available to common shareholders of $35.1 million;...

GlobeNewswire, Inc.

Declares Regular Quarterly Dividend Board Authorizes $20M Share Repurchase Program GARDEN CITY, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of...

GlobeNewswire, Inc.

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive...

GlobeNewswire, Inc.

Third Consecutive Quarter with Year-over-Year Revenue Growth GAAP Net Cash Provided by Operating Activities was $146 million, an increase of $74 million or 103% year-over-year.

GlobeNewswire, Inc.

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward an Investigational New Drug...

GlobeNewswire, Inc.

Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call...

GlobeNewswire, Inc.

Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab; Progressing Additional Cohorts...

GlobeNewswire, Inc.

Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved...